1WILDER - SMITH CH, ROHSS K, NILSSON - PIESCHL C, et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole. 20 mg in healthy volunteers[ J]. Digestion ,2003,68 : 184.
2LI XQ, ANDERSSO TB, AHLSTROME M, et al. Comparison of inhibitory effects of the proton pump - inhibitory drugs omeprazole,asomeprazole, lansoprazole, pantoprazole, and rebeprazole on humancytoc, hrome P450 activities [ J ]. DM D,2004,32 : 821.
3ROHASS K, LIND T, WILDER - SMITH C. Esomeprazole 40mg provides more effective intragastric acid control than lansoprazole 30mg,omeprazole 20mg, pantoprazole 40mg and rabeprazole 20mg in patients with gastro - oesophageal reflux symptoms [ J ] , Eur J Clin Pharmacol, 2004,60:531.
4GALMICHE JP, BRULEY Des VARANNES S, et al. Tenatoprazole,a novel proton pump inhibitor with a prolonged plasma half - life:effects on intragastric pH and comparison with esomeprazole in healthy volunteers[ J]. Aliment Pharmcol Ther,2004,19:655.
5GALMICHE JP,SACHER - HUVELIN S,BRULEY des VARANNES S,et al. A comparative study of the early effects of tenatoprazole 40mg and esomeprazole 40mg on intragastric pH in healthy volunteers[J]. Aliment Pharmacol Ther,2005 ,21:575.
6HUNT RH, ARMSTRONG D,JAMES C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half - life : comparison between tenstoprazole and esomeprazole on the duration of acid suppression in healthy male volunteer[J]. Am J Gastroenterol,2005, 100:1949.
7KWON D, CHAE JB, PARK CW, et al. Effects of IY - 81149, a newly developed proton pump inhibitor,on gastric acid secretion in vitro and in vivo[J]. Arzneimittelforschung,2001,51:204.
8KILL BJ, KIM IW,SHIN CY et al. Comparison of IY 81149 with omeprazole in rat reflux esophagitis [ J ]. J Auton Pharmaeol, 2000,20:291.
9ANDERSSSON K, AURELL HA,BRIVING C,et al. Preclinical profile of AZD 0865, a novel, selective, potassium - competitive acid blocker[ J ]. Gastroenterology,2004,126 : A 56.
10HOLSTEIN B, HOLMBERG A, FLORENTZSON M, et al. AZD 0865, a potassium - competitive acid blocker( P - CAB ), provides predictable inhibition of acid secretion with repeated dosing in the dog[J]. Eur J Pharm Sci,2004,.23(Supp 1) :S8.
9STANCIU GO. Gastroparesis and management[J]. Rev Med Chri Soc-Med Nat Lasi, 2001, 105(3): 451-456.
10LIND T, RYDBERG L, KYLEBACK A, et al. Rabeprazole pro- vides improved acid control vs.omeprazole in patients with symp- toms of gastro2oesopha2 geal reflux disease[J]. Aliment Pharmacol Ther, 1998, 12(11): 1079-1089.
